Pin Li

Pin Li

Auto-generated profile, based on publicly available information

Pin Li

Department of Biostatistics University of Michigan Ann Arbor Michigan USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
PHPeter G. Hawkins
Peter G. Hawkins
JLJae Y. Lee
Jae Y. Lee
YMYanping Mao
Yanping Mao
PLPin Li
Pin Li
MGMichael Green
Michael Green
Avraham EisbruchAvraham Eisbruch
Avraham Eisbruch

22 November 2021 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
PLPin Li
Pin Li
WZWei Zhao
Wei Zhao
SKScott Kaatz
Scott Kaatz
KLKatie Latack
Katie Latack
LSLonni Schultz
Lonni Schultz
LPLaila Poisson
Laila Poisson
COVID-19 induces coagulopathy manifested as elevation of dimerized plasmin fragment D (D-dimer) levels.1-5 As a result, patients with COVID-19 frequently experience both arterial thromboembolism (ATE) and venous thromboembolism (VTE). Bourguignon et al6 reported that pulmonary embolism and deep vein thrombosis occurred in 20.6% to 49.0% of patients with COVID-19 managed in intensive care units (ICUs). In many facilities, high-risk patients with COVID-19 are given anticoagulation (AC) at doses higher than the prophylactic dose for primary prophylaxis of VTE during their hospitalization.7-9 AC treatment in patients hospitalized with COVID-19 is associated with reduced mortality.10-12 Of note, the risk of ATE and VTE in patients with COVID-19 extends beyond their hospitalization. These thrombotic events are associated with readmission and mortality 90 days after discharge from the index admission. To mitigate the risk of VTE, a short-term course of AC has been used in patients with COVID-19 after their hospital discharge. This practice, however, is challenged by the low incidence of VTE in unselected patients with COVID-19. Giannis et al13 reported that 1.55% of patients with COVID-19 experienced VTE within 90 days after discharge. Universal prescription of postdischarge AC in patients with COVID-19 offers marginal clinical benefits and may cause harm in patients at high risk of bleeding. Given the unclear evidence, clinicians are facing the dilemma of which patients hospitalized with COVID-19 could benefit from postdischarge AC. We conducted a cohort study of patients with COVID-19 discharged from an inpatient hospital stay to assess the rate of postdischarge thrombosis in patients with COVID-19, identify the factors associated with the risk of postdischarge VTE, and evaluate the association of postdischarge AC use with VTE incidence.

1 January 2018 in Practical Radiation Oncology
Verified
Journal Article
Closed access
WJWilliam C. Jackson
William C. Jackson
RDRobert T. Dess
Robert T. Dess
DLDale W. Litzenberg
Dale W. Litzenberg
PLPin Li
Pin Li
MSMatthew Schipper
Matthew Schipper
DHDaniel A. Hamstra
Daniel A. Hamstra

14 November 2019 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
YCYue Cao
Yue Cao
MAMadhava Aryal
Madhava Aryal
PLPin Li
Pin Li
CLChoonik Lee
Choonik Lee
MSMatthew Schipper
Matthew Schipper
MMMichelle Mierzwa
Michelle Mierzwa
Purpose: FDG-PET adds to clinical factors, such tumor stage and p16 status, in predicting local (LF), regional (RF), and distant failure (DF) in poor prognosis locally advanced head and neck cancer (HNC) treated with chemoradiation. We hypothesized that MRI-based quantitative imaging (QI) metrics could add to clinical predictors of treatment failure more significantly than FDG-PET metrics. Materials and methods: Fifty four patients with poor prognosis HNCs who were enrolled in an IRB approved prospective adaptive chemoradiotherapy trial were analyzed. MRI-derived gross tumor volume (GTV), blood volume (BV), and apparent diffusion coefficient (ADC) pre-treatment and mid-treatment (fraction 10), as well as pre-treatment FDG PET metrics, were analyzed in primary and individual nodal tumors. Cox proportional hazards models for prediction of LRF and DF free survival were used to test the additional value of QI metrics over dominant clinical predictors. Results: The mean ADC pre-RT and its change rate mid-treatment were significantly higher and lower in p16– than p16+ primary tumors, respectively. A Cox model identified that high mean ADC pre-RT had a high hazard for LF and RF in p16– but not p16+ tumors (p = 0.015). Most interesting, persisting subvolumes of low BV (TVbv) in primary and nodal tumors mid-treatment had high-risk for DF (p < 0.05). Also, total nodal GTV mid-treatment, mean/max SUV of FDG in all nodal tumors, and total nodal TLG were predictive for DF (p < 0.05). When including clinical stage (T4/N3) and total nodal GTV in the model, all nodal PET parameters had a p-value of >0.3, and only TVbv of primary tumors had a p-value of 0.06. Conclusion: MRI-defined biomarkers, especially persisting subvolumes of low BV, add predictive value to clinical variables and compare favorably with FDG-PET imaging markers. MRI could be well-integrated into the radiation therapy workflow for treatment planning, response assessment, and adaptive therapy.

1 December 2020 in Oral Oncology
Verified
Journal Article
Closed access
LGLaila A. Gharzai
Laila A. Gharzai
PLPin Li
Pin Li
MSMatthew J. Schipper
Matthew J. Schipper
JYJohn Yao
John Yao
CMCharles S. Mayo
Charles S. Mayo
MMMichelle Mierzwa
Michelle Mierzwa

20 September 2020 in Journal of Biopharmaceutical Statistics
Verified
Journal Article
Closed access
PLPin Li
Pin Li
RLRachael Liu
Rachael Liu
JLJianchang Lin
Jianchang Lin
YJYuan Ji
Yuan Ji
Conventional dose finding designs in oncology drug development target on the identification of the maximum tolerated dose (MTD), with the assumption that the MTD has the most potential of clinical activity among those identified tolerable dose levels. However, immuno-oncology (I-O) and cell therapy area, may lack dose-efficacy monotonicity, posing significant challenges in the statistical designs for dose finding trials. A desirable design should empower the trial to identify the right dose level with tolerable toxicity and acceptable efficacy. Such dose is called as optimal biological dose (OBD), which is more appropriate to be considered as the primary objective of the first-in-human trial in I-O and cell therapy than MTD. We propose two model-assisted designs in this setting: the toxicity and efficacy probability interval-2 (TEPI-2) design and the utility-based interval (UBI) design that incorporate the toxicity and efficacy outcomes simultaneously and identify a dose that has high probability of acceptable efficacy with manageable toxicity. The proposed designs can generate decision tables before trial starts to facilitate practical and easy-to-implement applications. Through simulation studies, our proposed novel designs demonstrate superior performance in accuracy, efficiency, and safety. Additionally, they can reduce the number of patients and shorten clinical development timeline. We also illustrate the advantages of proposed methods by redesigning a CAR T-cell therapy phase I clinical trial for multiple myeloma and summarize our recommendations in the discussion section.